Hannah E Brown1,2, Oliver Freudenreich1, Xiaoduo Fan3, Stephen O Heard4, Donald Goff5, George Petrides6, Amy L Harrington3, John M Kane6,7,8,9, Heidi Judge1, Bettina Hoeppner1, Maurizio Fava1, Roy H Perlis1. 1. Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston. 2. Department of Psychiatry, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts. 3. Department of Psychiatry, UMass Memorial Health Care and UMass Medical School, Worcester, Massachusetts. 4. Department of Anesthesiology and Perioperative Medicine, UMass Memorial Health Care and UMass Medical School, Worcester, Massachusetts. 5. Department of Psychiatry, NYU Langone Medical Center, New York, New York. 6. Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, New York. 7. Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, New York. 8. Department of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York. 9. Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
Abstract
Importance: Antipsychotic medications for the treatment of schizophrenia have limitations, and new treatments are needed. A prior pilot investigation suggested that adjunctive sodium nitroprusside (SNP) administered intravenously had rapid efficacy in the treatment of patients with schizophrenia. Objective: To determine the efficacy and tolerability of intravenous SNP infused at a rate of 0.5 μg/kg/min for 4 hours in patients with schizophrenia with some degree of treatment resistance. Design, Setting, and Participants: Multicenter, randomized, double-blind acute treatment study using a sequential parallel comparison design conducted in two 2-week phases at 4 academic medical centers beginning May 20, 2015, and ending March 31, 2017. Participants were adults 18 to 65 years of age with a diagnosis of schizophrenia as confirmed by the Structured Clinical Interview for DSM-IV, taking antipsychotic medication for at least 8 weeks, and had at least 1 failed trial of an antipsychotic medication within the past year. A total of 90 participants consented, 60 participants enrolled, and 52 participants were included in the analyses. A modified intent-to-treat analysis was used. Interventions: Participants were randomized in a 1:1:1 ratio to 1 of 3 treatment sequences: SNP and SNP, placebo and SNP, and placebo and placebo. The SNP and SNP group received SNP in phase 1 and SNP in phase 2 for the purpose of blinding, but the data from phase 2 were not included in the results. The placebo and SNP group received placebo in phase 1 and SNP in phase 2. If there was no response to placebo in phase 1, data from phase 2 were included in the analyses. The placebo and placebo group received placebo in both phases; if there was no response to placebo in phase 1, data from phase 2 were included in the analyses. Main Outcomes and Measures: Effectiveness of SNP compared with placebo in improving Positive and Negative Syndrome Scale (PANSS) total, positive, and negative scores across each 2-week phase. Results: Fifty-two participants (12 women and 40 men) were included in the study. In the SNP and SNP group, the mean (SD) age was 47.1 (10.5) years. In the placebo and SNP group, the mean (SD) age was 45.9 (12.3) years. In the placebo and placebo group, the mean (SD) age was 40.4 (11.0) years. There were no significant differences between the SNP and placebo groups at baseline or in change from baseline for PANSS-total (weighted β = -1.04; z = -0.59; P = .57), PANSS-positive (weighted β = -0.62; z = -0.93; P = .35), or PANSS-negative (weighted β = -0.12; z = -0.19; P = .85) scores. No significant differences in safety or tolerability measures were identified. Conclusions and Relevance: Although intravenous SNP is well tolerated, it was not an efficacious adjunctive treatment of positive or negative symptoms of psychosis among outpatients with schizophrenia with prior history of treatment resistance. Trial Registration: ClinicalTrials.gov identifier: NCT02164981.
RCT Entities:
Importance: Antipsychotic medications for the treatment of schizophrenia have limitations, and new treatments are needed. A prior pilot investigation suggested that adjunctive sodium nitroprusside (SNP) administered intravenously had rapid efficacy in the treatment of patients with schizophrenia. Objective: To determine the efficacy and tolerability of intravenous SNP infused at a rate of 0.5 μg/kg/min for 4 hours in patients with schizophrenia with some degree of treatment resistance. Design, Setting, and Participants: Multicenter, randomized, double-blind acute treatment study using a sequential parallel comparison design conducted in two 2-week phases at 4 academic medical centers beginning May 20, 2015, and ending March 31, 2017. Participants were adults 18 to 65 years of age with a diagnosis of schizophrenia as confirmed by the Structured Clinical Interview for DSM-IV, taking antipsychotic medication for at least 8 weeks, and had at least 1 failed trial of an antipsychotic medication within the past year. A total of 90 participants consented, 60 participants enrolled, and 52 participants were included in the analyses. A modified intent-to-treat analysis was used. Interventions: Participants were randomized in a 1:1:1 ratio to 1 of 3 treatment sequences: SNP and SNP, placebo and SNP, and placebo and placebo. The SNP and SNP group received SNP in phase 1 and SNP in phase 2 for the purpose of blinding, but the data from phase 2 were not included in the results. The placebo and SNP group received placebo in phase 1 and SNP in phase 2. If there was no response to placebo in phase 1, data from phase 2 were included in the analyses. The placebo and placebo group received placebo in both phases; if there was no response to placebo in phase 1, data from phase 2 were included in the analyses. Main Outcomes and Measures: Effectiveness of SNP compared with placebo in improving Positive and Negative Syndrome Scale (PANSS) total, positive, and negative scores across each 2-week phase. Results: Fifty-two participants (12 women and 40 men) were included in the study. In the SNP and SNP group, the mean (SD) age was 47.1 (10.5) years. In the placebo and SNP group, the mean (SD) age was 45.9 (12.3) years. In the placebo and placebo group, the mean (SD) age was 40.4 (11.0) years. There were no significant differences between the SNP and placebo groups at baseline or in change from baseline for PANSS-total (weighted β = -1.04; z = -0.59; P = .57), PANSS-positive (weighted β = -0.62; z = -0.93; P = .35), or PANSS-negative (weighted β = -0.12; z = -0.19; P = .85) scores. No significant differences in safety or tolerability measures were identified. Conclusions and Relevance: Although intravenous SNP is well tolerated, it was not an efficacious adjunctive treatment of positive or negative symptoms of psychosis among outpatients with schizophrenia with prior history of treatment resistance. Trial Registration: ClinicalTrials.gov identifier: NCT02164981.
Authors: Stefan Leucht; John M Kane; Werner Kissling; Johannes Hamann; Eva Etschel; Rolf R Engel Journal: Schizophr Res Date: 2005-06-27 Impact factor: 4.939
Authors: Kristen J Brennand; Anthony Simone; Jessica Jou; Chelsea Gelboin-Burkhart; Ngoc Tran; Sarah Sangar; Yan Li; Yangling Mu; Gong Chen; Diana Yu; Shane McCarthy; Jonathan Sebat; Fred H Gage Journal: Nature Date: 2011-04-13 Impact factor: 49.962
Authors: Joao Paulo Maia-de-Oliveira; Joao Abrao; Paulo R Evora; Antonio W Zuardi; Jose A S Crippa; Paulo Belmonte-de-Abreu; Glen B Baker; Serdar M Dursun; Jaime E C Hallak Journal: J Clin Psychopharmacol Date: 2015-02 Impact factor: 3.153
Authors: J M Stone; P D Morrison; I Koychev; F Gao; T J Reilly; M Kolanko; A Mohammadinasab; S Kapur; P K McGuire Journal: Psychol Med Date: 2016-09-22 Impact factor: 7.723
Authors: Daniel G Hottinger; David S Beebe; Thomas Kozhimannil; Richard C Prielipp; Kumar G Belani Journal: J Anaesthesiol Clin Pharmacol Date: 2014-10
Authors: Kate Merritt; Ana Catalan; Samuel Cowley; Arsime Demjaha; Matthew Taylor; Philip McGuire; Ruth Cooper; Paul Morrison Journal: J Psychopharmacol Date: 2020-05-21 Impact factor: 4.153